Potential adverse events with biologic response modifiers - Monoclonal Antibodies

Potential adverse events with biologic response modifiers
2 May 2006
James S.W. Kong, Suzanne S. Teuber and M. Eric Gershwin
Autoimmunity Reviews
Abstract
In recent years, an explosion of biologic response modifiers has entered the market to combat a variety of immune mediated diseases. These can be in the form of recombinant cytokines, as in the case of interferon beta in the treatment of multiple sclerosis, or novel engineered antibodies can be constructed by combining non-human determinants with a human immunoglobulin scaffold, as in the case of omalizumab in the treatment of allergic asthma. More recently, completely human monoclonal antibodies have also been constructed. Adverse reactions related to these agents can be classified as expected or unexpected events. A number of case studies and a handful of randomized trials have demonstrated the potential toxicities with the use of biologic response modifiers. This article aims to review adverse events profiles of select biologic response modifiers for which the most data is available that are common to a rheumatology, allergy/immunology, and dermatology patient population.
Keywords: Tissue necrosis factor; Monoclonal antibodies; Biologic response modifiers; Adverse events
A subscription is required to view the complete article.